Project Grant R21AI194334
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$228K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
The federal Project Grant award R01AI191807, with $507,792.00 in funding, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to determine the role of the precursor HIV-1 protease (PR) in the development of drug resistance to protease inhibitors (PIs). Key objectives include assessing how mutations in PR or the cleavage site influence precursor and mature PR function, evaluating...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $439,688 to Yale University to identify inhibitors of the HIV Rev-Rev interaction through a high-throughput, small molecule, cell-free screening approach. The goal is to develop a first-in-class anti-Rev molecule capable of interfering with the function of this essential regulatory gene of HIV, thereby expanding the available therapeutics...
This Project Grant award of $438,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop new tools to facilitate drug discovery for pathogen proteasomes. The funded project at the University of California, San Diego aims to address two key bottlenecks in advancing research on parasite proteasomes - the difficulty in isolating and purifying parasite 20S proteasome enzymes,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $492,980 to the University of Virginia (UVA) to investigate how variations in the HIV Rev-Rev Response Element (Rev-RRE) regulatory system impact viral transmission and latency. The project aims to define the role of Rev-RRE variation in sexual transmission, explore the contribution of the Rev-RRE axis to latency...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $223,300.00 to Emory University to develop novel HIV capsid-targeting antivirals that can maintain activity against lenacapavir-resistant viruses. The research aims to synthesize and characterize analogs of lead compounds that can bind the HIV capsid protein and target clinically-relevant mutations conferring...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616 to Emory University to develop virus-like particles (VLPs) for use in HIV-1 cure strategies. The key products and services to be delivered under this 18-month project include: Using VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, as part of a "shock and kill" strategy to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $847,141 to investigate the role of HIV-1 integrase (IN) in virion morphogenesis and target it with novel allosteric integrase inhibitors. The research aims to delineate the sequence and structural features of viral RNA recognized by HIV-1 IN and determine cryo-EM structures of IN tetramers bound to cognate viral RNA...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $220,224 to the University of Chicago to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to gain a deeper mechanistic understanding of HIV assembly, maturation, and uncoating processes, with a focus on the roles of viral RNA, host cell factors, and...